NCT00343460 2026-03-02
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
Phase 3 Completed
Clinical Trials
10 trialsNCT01596413 2024-07-26
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
Kyowa Kirin Co., Ltd.
Phase 1 Withdrawn
NCT01596426 2024-07-26
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
Kyowa Kirin Co., Ltd.
Phase 1 Withdrawn
NCT01596400 2024-06-17
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT03333824 2019-03-25
Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer
AstraZeneca
Phase 1 Completed
NCT01636947 2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT02563951 2016-01-08
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
Maxinase Life Sciences Ltd.
Phase 1 Completed
NCT01909856 2015-12-04
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT01767714 2014-12-09
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
Sanofi
Phase 3 Completed